BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36455197)

  • 21. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations.
    Hofmann I; Avagyan S; Stetson A; Guo D; Al-Sayegh H; London WB; Lehmann L
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1124-1130. PubMed ID: 32088370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.
    McReynolds LJ; Yang Y; Yuen Wong H; Tang J; Zhang Y; Mulé MP; Daub J; Palmer C; Foruraghi L; Liu Q; Zhu J; Wang W; West RR; Yohe ME; Hsu AP; Hickstein DD; Townsley DM; Holland SM; Calvo KR; Hourigan CS
    Leuk Res; 2019 Jan; 76():70-75. PubMed ID: 30578959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolution of cellular deficiency in GATA2 mutation.
    Dickinson RE; Milne P; Jardine L; Zandi S; Swierczek SI; McGovern N; Cookson S; Ferozepurwalla Z; Langridge A; Pagan S; Gennery A; Heiskanen-Kosma T; Hämäläinen S; Seppänen M; Helbert M; Tholouli E; Gambineri E; Reykdal S; Gottfreðsson M; Thaventhiran JE; Morris E; Hirschfield G; Richter AG; Jolles S; Bacon CM; Hambleton S; Haniffa M; Bryceson Y; Allen C; Prchal JT; Dick JE; Bigley V; Collin M
    Blood; 2014 Feb; 123(6):863-74. PubMed ID: 24345756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of GATA2-related myeloid neoplasms.
    Hirabayashi S; Wlodarski MW; Kozyra E; Niemeyer CM
    Int J Hematol; 2017 Aug; 106(2):175-182. PubMed ID: 28643018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency.
    Chiu CY; Matsuo T; Wurster S; Gerstein Y; Hammond DE; Chien KS; DiNardo C; Kontoyiannis DP
    Mycoses; 2023 Dec; 66(12):1029-1034. PubMed ID: 37550272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation.
    Sato Y; Fukatsu M; Suzuki T; Sasajima T; Gunji N; Yoshida S; Asano N; Fukuchi K; Mori H; Takano M; Hayashi K; Takahashi H; Shirado-Harada K; Kimura S; Koyama D; Migita K; Ikezoe T
    Int J Hematol; 2023 Nov; 118(5):642-646. PubMed ID: 37084069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GATA 2 Deficiency: Focus on Immune System Impairment.
    Fabozzi F; Mastronuzzi A; Ceglie G; Masetti R; Leardini D
    Front Immunol; 2022; 13():865773. PubMed ID: 35769478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
    Lübking A; Vosberg S; Konstandin NP; Dufour A; Graf A; Krebs S; Blum H; Weber A; Lenhoff S; Ehinger M; Spiekermann K; Greif PA; Cammenga J
    Leuk Res Rep; 2015; 4(2):72-5. PubMed ID: 26716079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative and qualitative impairments in GATA2 and myeloid neoplasms.
    Shimizu R; Yamamoto M
    IUBMB Life; 2020 Jan; 72(1):142-150. PubMed ID: 31675473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.
    Wlodarski MW; Hirabayashi S; Pastor V; Starý J; Hasle H; Masetti R; Dworzak M; Schmugge M; van den Heuvel-Eibrink M; Ussowicz M; De Moerloose B; Catala A; Smith OP; Sedlacek P; Lankester AC; Zecca M; Bordon V; Matthes-Martin S; Abrahamsson J; Kühl JS; Sykora KW; Albert MH; Przychodzien B; Maciejewski JP; Schwarz S; Göhring G; Schlegelberger B; Cseh A; Noellke P; Yoshimi A; Locatelli F; Baumann I; Strahm B; Niemeyer CM;
    Blood; 2016 Mar; 127(11):1387-97; quiz 1518. PubMed ID: 26702063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic heterogeneity associated with germline
    Haddox CL; Carr RM; Abraham RS; Perez Botero J; Rodriguez V; Pardanani A; Patnaik MM
    Leuk Lymphoma; 2019 Dec; 60(13):3282-3286. PubMed ID: 31246134
    [No Abstract]   [Full Text] [Related]  

  • 32. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.
    Wang X; Muramatsu H; Okuno Y; Sakaguchi H; Yoshida K; Kawashima N; Xu Y; Shiraishi Y; Chiba K; Tanaka H; Saito S; Nakazawa Y; Masunari T; Hirose T; Elmahdi S; Narita A; Doisaki S; Ismael O; Makishima H; Hama A; Miyano S; Takahashi Y; Ogawa S; Kojima S
    Haematologica; 2015 Oct; 100(10):e398-401. PubMed ID: 26022708
    [No Abstract]   [Full Text] [Related]  

  • 33. A novel GATA2 distal enhancer mutation results in MonoMAC syndrome in 2 second cousins.
    West RR; Bauer TR; Tuschong LM; Embree LJ; Calvo KR; Tillo D; Davis J; Holland SM; Hickstein DD
    Blood Adv; 2023 Oct; 7(20):6351-6363. PubMed ID: 37595058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.
    Kazenwadel J; Secker GA; Liu YJ; Rosenfeld JA; Wildin RS; Cuellar-Rodriguez J; Hsu AP; Dyack S; Fernandez CV; Chong CE; Babic M; Bardy PG; Shimamura A; Zhang MY; Walsh T; Holland SM; Hickstein DD; Horwitz MS; Hahn CN; Scott HS; Harvey NL
    Blood; 2012 Feb; 119(5):1283-91. PubMed ID: 22147895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and molecular characteristics of GATA2 related pediatric primary myelodysplastic syndrome].
    An WB; Liu C; Wan Y; Chen XY; Guo Y; Chen XJ; Yang WY; Chen YM; Zhang YC; Zhu XF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):477-483. PubMed ID: 31340620
    [No Abstract]   [Full Text] [Related]  

  • 36. Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency.
    Rein A; Geron I; Kugler E; Fishman H; Gottlieb E; Abramovich I; Giladi A; Amit I; Mulet-Lazaro R; Delwel R; Gröschel S; Levin-Zaidman S; Dezorella N; Holdengreber V; Rao TN; Yacobovich J; Steinberg-Shemer O; Huang QH; Tan Y; Chen SJ; Izraeli S; Birger Y
    Haematologica; 2023 Sep; 108(9):2316-2330. PubMed ID: 36475518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA2 Deficiency in Adult Life Is Characterized by Phenotypic Diversity and Delayed Diagnosis.
    Shamriz O; Zahalka N; Simon AJ; Lev A; Barel O; Mor N; Tal Y; Segel MJ; Somech R; Yonath H; Toker O
    Front Immunol; 2022; 13():886117. PubMed ID: 35603181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency.
    Kozyra EJ; Pastor VB; Lefkopoulos S; Sahoo SS; Busch H; Voss RK; Erlacher M; Lebrecht D; Szvetnik EA; Hirabayashi S; Pasaulienė R; Pedace L; Tartaglia M; Klemann C; Metzger P; Boerries M; Catala A; Hasle H; de Haas V; Kállay K; Masetti R; De Moerloose B; Dworzak M; Schmugge M; Smith O; Starý J; Mejstrikova E; Ussowicz M; Morris E; Singh P; Collin M; Derecka M; Göhring G; Flotho C; Strahm B; Locatelli F; Niemeyer CM; Trompouki E; Wlodarski MW;
    Leukemia; 2020 Oct; 34(10):2673-2687. PubMed ID: 32555368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin manifestations among GATA2-deficient patients.
    Polat A; Dinulescu M; Fraitag S; Nimubona S; Toutain F; Jouneau S; Poullot E; Droitcourt C; Dupuy A
    Br J Dermatol; 2018 Mar; 178(3):781-785. PubMed ID: 28440875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency.
    Wu Z; Gao S; Diamond C; Kajigaya S; Chen J; Shi R; Palmer C; Hsu AP; Calvo KR; Hickstein DD; Holland SM; Young NS
    Blood Adv; 2020 Jun; 4(12):2656-2670. PubMed ID: 32556286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.